In vitro effects of arsenic trioxide, interferon α and zidovudine in adult T cell leukemia/lymphoma cells

Hachiman,Miho; Yoshimitsu,Makoto; Ezinne,Chibueze; Kuroki,Ayako; Kozako,Tomohiro; Arima,Naomichi

doi:10.3892/ol.2018.8771

In vitro effects of arsenic trioxide, interferon α and zidovudine in adult T cell leukemia/lymphoma cells

Authors:
- Miho Hachiman
- Makoto Yoshimitsu
- Chibueze Ezinne
- Ayako Kuroki
- Tomohiro Kozako
- Naomichi Arima
View Affiliations

Affiliations: Division of Hematology and Immunology, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8544, Japan, Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814‑0180, Japan
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8771
Pages: 1305-1311

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the efficacy of combination chemotherapy with arsenic trioxide (ATO), interferon α (IFN) and zidovudine (AZT) for adult T cell leukemia/lymphoma (ATL), the precise mechanism underlying this combination treatment effect is unknown. In the present study, ATO/IFN/AZT was examined in an ATL leukemic cell line (S1T, non‑Tax expressing), a human T‑lymphotropic virus 1 (HTLV‑1)‑infected cell line (MT2, Tax‑expressing) and primary ATL cells from patients with acute and chronic ATL. IFN/AZT marginally inhibited MT2 cell proliferation, but substantially inhibited S1T cell proliferation. IFN/AZT increased the cleavage of numerous caspases and PARP in S1T cells, and regulated the signal transducer and activator of transcription 1 and nuclear factor‑κB signaling pathway. These effects represent the potential anti‑ATL mechanisms of INF/AZT in vitro. In addition, the combination of ATO and IFN/AZT demonstrated synergistic effects on S1T cells. Therefore, the Tax‑independent mechanism underlying the anti‑ATL effect of ATO must be further elucidated.

View Figures

View References

1	Ishitsuka K and Tamura K: Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 15:e517–e526. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, et al: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 25:5458–64. 2007. View Article : Google Scholar : PubMed/NCBI
3	Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, et al: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood. 116:1369–1376. 2010. View Article : Google Scholar : PubMed/NCBI
4	Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, Koda K, Iyama S, Kuroda H, Tsutsumi Y, Imamura M and Teshima T: High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transpl. 20:801–805. 2014. View Article : Google Scholar
5	Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, et al: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol. 30:837–842. 2012. View Article : Google Scholar : PubMed/NCBI
6	Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G and Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 28:4177–4183. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bazarbachi A, Nasr R, El-Sabban ME, Mahé A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, et al: Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia. 14:716–721. 2000. View Article : Google Scholar : PubMed/NCBI
8	Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, et al: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 113:6528–6532. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H and Bazarbachi A: ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation. Blood. 125:474–482. 2015. View Article : Google Scholar : PubMed/NCBI
10	Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y and Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 109:559–567. 2004. View Article : Google Scholar : PubMed/NCBI
11	Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 79:428–437. 1991. View Article : Google Scholar : PubMed/NCBI
12	Arima N, Molitor JA, Smith MR, Kim JH, Daitoku Y and Greene WC: Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: Evidence for a pretranslational component of regulation. J Virol. 65:6892–6899. 1991.PubMed/NCBI
13	Takemoto S, Matsuoka M, Yamaguchi K and Takatsuki K: A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood. 84:3080–3085. 1994.PubMed/NCBI
14	Yoshida M, Miyoshi I and Hinuma Y: A retrovirus from human leukemia cell lines: Its isolation, characterization, and implication in human adult T-cell leukemia (ATL). Princess Takamatsu Symp. 12:285–294. 1982.PubMed/NCBI
15	Lee B, Tanaka Y and Tozawa H: Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I. Tohoku J Exp Med. 157:1–11. 1989. View Article : Google Scholar : PubMed/NCBI
16	Szumiel I and Nias AH: Isobologram analysis of the combined effects of anti-tumour platinum complexes and ionizing radiation on mammalian cells. Br J Cancer. 42:292–296. 1980. View Article : Google Scholar : PubMed/NCBI
17	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 48:452–458. 2013. View Article : Google Scholar
18	Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, et al: Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 397:441–446. 1999. View Article : Google Scholar : PubMed/NCBI
19	El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de Thé H and Bazarbachi A: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 96:2849–2855. 2000.PubMed/NCBI
20	Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 279:5811–5820. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lin J, Tang H, Jin X, Jia G and Hsieh JT: p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene. 21:3082–3088. 2002. View Article : Google Scholar : PubMed/NCBI
22	Ramana CV, Chatterjee-Kishore M, Nguyen H and Stark GR: Complex roles of Stat1 in regulating gene expression. Oncogene. 19:2619–2627. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T, Tanaka Y, Utsunomiya A and Kannagi M: Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 10:522013. View Article : Google Scholar : PubMed/NCBI
24	Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O and de Thé H: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 93:278–283. 1999.PubMed/NCBI
25	Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, de Thé H and Bazarbachi A: Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 101:4576–4582. 2003. View Article : Google Scholar : PubMed/NCBI
26	Brown M, Bellon M and Nicot C: Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood. 109:1653–1659. 2007. View Article : Google Scholar : PubMed/NCBI